Numoda Capital Innovations: Numoda Lawsuit

We are the unique investment and business advisory partner to life sciences companies. We provide new means for capital to reach promising life sciences companies – and we open access to emerging medical technologies for potential partners seeking tomorrow’s therapies and treatments.

Our life sciences fund fuels new drug development projects that meet our strict criteria. It offers investors opportunities to gain reward from drugs in development under the industry leading guidance of our affiliate, Numoda Corporation.

We have proprietary methods to help promising life sciences companies attract capital, improve clinical development norms, structure advantageous deals and secure partnering arrangements. Our Numoda Capital Innovations fund invests in firms whose clinical trials are managed by Numoda Corporation and whom we are confident have bright prospects for growth and commercial success.

We are the investment fund affiliate of Numoda Corporation, the life sciences services company, and Numoda Technologies, the industry leader in innovative platforms for clinical trial oversight, logistics, financial management, and systems integration. Together, the three companies represent a new, proven model for advancing and commercializing life science companies whose therapies and treatments extend life and improve the quality of life.

Provectus with Numoda

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), signed an agreement
with Numoda Capital Innovations LLC (http://www.numodacapital.com) to license its TruPoints® strategic
partnering platform. Provectus plans to make PH-10, a therapy treatment of serious dermatological diseases,
which recently showed positive Phase 2 clinical trial results in both Atopic Dermatitis and Psoriasis. In pursuit
of this development, the company will use Numoda’s TruPoints to facilitate transactions with potential licensing
partners for PH-10 and it will organize all due diligence material relating to the Phase 2 clinical trials.
The desired outcome of the agreement is to improve the flow of information to potential licensees. Numoda’s
TruPoints platform already has an excellent reputation for helping numerous development stage biotech
companies secure big pharma licensing agreements.Craig Dees, Ph.D., CEO of Provectus said, “As we
actively seek to out-license PH-10, Numoda TruPoints will enable the exchange of scientific and business
information between Provectus and potential partners. We expect this platform to play a critical role in the outlicensing
process when we formally engage an investment banker.” As for today, the Provectus-Numoda deal
is already creating some buzz and showing consumer confidence with it's margins up by over 3% since the
previous close.
Page

Build your own Numoda

http://numoda.com/pages/byon.html

Numoda Lawsuit

Rules of procedure and complications in lawsuits

Rules of criminal or civil procedure govern the conduct of a lawsuit in the common law adversarial system of dispute resolution. Procedural rules are additionally constrained/informed by separate statutory laws, case law, and constitutional provisions that define the rights of the parties to a lawsuit (see especially due process), though the rules will generally reflect this legal context on their face. The details of procedure differ greatly from jurisdiction to jurisdiction, and often from court to court within the same jurisdiction. The rules are very important for litigants to know, however, because they dictate the timing and progression of the lawsuit—what may be filed and when, to obtain what result. Failure to comply with the procedural rules may result in serious limitations upon the ability to present claims or defenses at any subsequent trial, or even dismissal of the lawsuit.

Though the majority of lawsuits are settled and never reach trial,^[3] they can be very complicated to litigate. This is particularly true in federal systems, where a federal court may be applying state law (e.g., the Eriedoctrine in the United States) or vice versa, or one state applying the law of another, and where it additionally may not be clear which level (or location) of court actually has jurisdiction over the claim or personal jurisdiction over the defendant. For example, about 98 percent of civil cases in the United States federal courts are resolved without a trial. Domestic courts are also often called upon to apply foreign law, or to act upon foreign defendants, over whom they may not, as a practical matter, even have the ability to enforce a judgment if the defendant's assets are outside their reach.

Lawsuits become additionally complicated as more parties become involved (see joinder). Within a "single" lawsuit, there can be any number of claims and defenses (all based on numerous laws) between any number of plaintiffs or defendants, each of whom can bring any number of cross-claims and counterclaims against each other, and even bring additional parties into the suit on either side after it progresses. However, courts typically have some power to sever claims and parties into separate actions if it is more efficient to do so, such as if there is not a sufficient overlap of factual issues between the various associates.

Welcome| Numoda Corporation

Numoda is the pioneer of a new model for supporting life sciences companies as they move from clinical development of innovative treatments to ultimate relationships with marketing partners.

Our model aligns with both sponsor and vendor needs, addressing the broader issues that active and complex clinical trials face, by providing a single integrated location your entire trial.

The Numoda approach – which has been proven across scores of relationships – calls for Numoda to share the risk with promising life sciences companies by assisting in business functions such as budgeting and logistics, and to apply patented information technologies and management expertise to achieve the successful completion of vital clinical trials.

The result is a unique partnership between Numoda’s finance, technology, and trial management specialists and innovative companies that, in the process, become better able to develop life-enhancing and life-saving treatments for the health of consumers of the future

Numoda Corporation: Events

Cowen Group 31st Annual Healthcare Conference
March 7-9, 2011, Boston MA

JP Morgan 11th Annual Healthcare Conference
January 10-13, 2011, New York NY

Biotech Showcase 2011
January 10-12, 2011, San Francisco – Union Square

One Med Forum
January 11-13th, 2011, San Francisco

Rodman & Renshaw 12th Annual Healthcare Conference 
September 12-15, 2010, New York NY

Canaccord Adams Global Growth Conference
August 10-13, 2010, Boston, MA

BMO Capital Markets, 10th Annual Focus on Healthcare Conference
August 5, 2010, New York, NY

Numoda Corporation: Client Success

Client Success

Our norms beat the industry by an improved rate of more than 50% in every major area of the clinical trial process. From enrollment, to speed and data quality, to the overall success rate, Numoda Technologies’ results speak for themselves.

The results - Some metrics
Norms	Industry	NT	Improved
SUCCESS RATE: In Phase III Clinical Trials	59%(1) (50% in oncology)	>90%	>53%
ENROLLMENT: Percent of invalid patients enrolled	7.5% (EDC)-15%(paper)(2)	<1%	>86%-93%
DATA QUALITY: Queries/page of patient data	1(3)	<0.4	>60%
SPEED: Study database start-up Time needed to database lock after last patient data	51.5 days(4) >65 days(3)	<21 days Hours	>62% >30X
(1) Lehman Brothers, 2006 “Late-Stage R&D Productivity: A Lehman Look at European Pharma R&D.” (2) Dr. Thomas Bart, “Comparison of Electronic Data Capture with Paper Data Collection,” Pharmwatch, 2003. (3) Kola and Landis, “Can the pharmaceutical industry reduce attrition rates?;” Nature Rev Drug Discovery. 3, 711-715 (2004); Practical Guide to Clinical Data Management, Second Edition, p. 66; INC Research. (4) Fitzmartin RD, Drug Information Journal 2001; 35:671-679

Our libraries of case histories are full of countless tales of trials rescued, such as these:

• Having failed two clinical trials based on data inconsistencies, a biopharma, after running a new trial with our services, was able to receive FDA approval which led them to $200MM in annual sales.
• A medical device company with 6,000 queries, 600 SAEs and a previous FDA failure was able to receive FDA approval in addition to $400MM deal with Johnson & Johnson after partnering with us.
• A biotech that had failed 50% of all its trials completed a successful trial and thereafter was able to secure $1.4 billion partnership with GlaxoSmithKline as a result of our partnership.

We pride ourselves on the successes of our clients.